Emil L Fosbøl1, Rasmus Rørth2, Birgitte Pernille Leicht3, Morten Schou4, Mathew S Maurer5, Søren Lund Kristensen6, Lars Kober2, Finn Gustafsson2. 1. The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. Electronic address: elf@heart.dk. 2. The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. 3. Department of Orthopedic Surgery, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. 4. Department of Cardiology, Herlev and Gentofte University Hospital, Hellerup, Denmark. 5. Columbia University Medical Center, New York, New York. 6. Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark.
Abstract
BACKGROUND: Recent studies have suggested that transthyretin amyloidosis (ATTR) is a more common cause of heart failure (HF) than previously appreciated, and novel treatments for amyloidosis are emerging. About one-half of patients with ATTR cardiac amyloidosis have a history of carpal tunnel syndrome (CTS). OBJECTIVES: This study examined the risk of amyloidosis, HF, and other adverse cardiovascular outcomes associated with CTS relative to control subjects without CTS. METHODS: Using Danish nationwide registries from 1996 to 2012, 56,032 patients were identified who underwent surgical treatment for CTS, and they were compared with a sex- and age-matched cohort (ratio 1:1) from the general population to examine their risk of amyloidosis, HF, and other adverse cardiovascular outcomes. Cumulative incidence curves and Cox proportional hazard models were used to assess differences. RESULTS: As expected, CTS was associated with a future diagnosis of amyloidosis (hazard ratio: 12.12 [95% confidence interval: 4.37 to 33.60]). CTS was associated with a higher incidence of HF, and this held true in the adjusted analysis yielding a hazard ratio of 1.54 (95% confidence interval: 1.45 to 1.64). No significant interaction with sex was found (p = 0.5). Risk of other adverse outcomes was also associated with CTS (p < 0.0001 for atrial fibrillation, atrioventricular heart block, and pacemaker implantation). CONCLUSIONS: Patients who undergo surgical treatment for CTS are associated with a higher risk of amyloidosis and HF relative to matched control subjects from the general population. Other cardiovascular outcomes were also increased with CTS.
BACKGROUND: Recent studies have suggested that transthyretin amyloidosis (ATTR) is a more common cause of heart failure (HF) than previously appreciated, and novel treatments for amyloidosis are emerging. About one-half of patients with ATTRcardiac amyloidosis have a history of carpal tunnel syndrome (CTS). OBJECTIVES: This study examined the risk of amyloidosis, HF, and other adverse cardiovascular outcomes associated with CTS relative to control subjects without CTS. METHODS: Using Danish nationwide registries from 1996 to 2012, 56,032 patients were identified who underwent surgical treatment for CTS, and they were compared with a sex- and age-matched cohort (ratio 1:1) from the general population to examine their risk of amyloidosis, HF, and other adverse cardiovascular outcomes. Cumulative incidence curves and Cox proportional hazard models were used to assess differences. RESULTS: As expected, CTS was associated with a future diagnosis of amyloidosis (hazard ratio: 12.12 [95% confidence interval: 4.37 to 33.60]). CTS was associated with a higher incidence of HF, and this held true in the adjusted analysis yielding a hazard ratio of 1.54 (95% confidence interval: 1.45 to 1.64). No significant interaction with sex was found (p = 0.5). Risk of other adverse outcomes was also associated with CTS (p < 0.0001 for atrial fibrillation, atrioventricular heart block, and pacemaker implantation). CONCLUSIONS:Patients who undergo surgical treatment for CTS are associated with a higher risk of amyloidosis and HF relative to matched control subjects from the general population. Other cardiovascular outcomes were also increased with CTS.
Authors: Henrik C Bäcker; Samuel E Galle; Suzanne Lentzsch; Christina E Freibott; Seth Shoap; Robert J Strauch; Melvin P Rosenwasser Journal: Ir J Med Sci Date: 2021-10-28 Impact factor: 2.089